Want to join the conversation?
$REGN and $TEVA announced global agreement to develop and commercialize fasinumab, investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. $TEVA will pay $REGN $250MM upfront and share equally in global commercial value as well as ongoing R&D costs of about $1Bil.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!